It is recommended to include CD 3, CD 20, CD 10, BCL6, BCL2, C-MYC, CD30, Ki-67, MUM1, and cyclin D19 to confirm diagnosis, document cell of origin(COO), and differentiate DLBCL from double-expressor lymphomas (DEL).For characteristic morphology with CD20-negative biopsy, CD138 andleukocyte common antigen are indicated to rule out plasmablasticlymphoma. Here, BCL2 is linked to diffuse large B-cell lymphoma.